Chen, Hao
Ambadapadi, Sriram
Wakefield, Dara
Bartee, Meeyong
Yaron, Jordan R. http://orcid.org/0000-0002-4133-474X
Zhang, Liqiang
Archer-Hartmann, Stephanie A.
Azadi, Parastoo
Burgin, Michelle
Borges, Chad
Zheng, Donghang
Ergle, Kevin
Muppala, Vishnu
Morshed, Sufi
Rand, Kenneth
Clapp, William
Proudfoot, Amanda
Lucas, Alexandra
Funding for this research was provided by:
National Institutes of Health
American Heart Association (0855421 E, 12GRNT120/0313, and 17GRNT33460327)
University of Florida / Gatorade fund National Institute of Health
Article History
Received: 19 April 2018
Accepted: 24 August 2018
First Online: 7 September 2018
Competing Interests
: For potential COI, we would note that Dr. A. Lucas has previously been affiliated with a small Biotechnology company in Canada, but that company was not involved in this research and is no longer functioning. Dr. Lucas has submitted patents on M-T7 and to <i>Ndst1</i> modification with antisense oligonucleotides to <i>Ndst1</i> in transplant. We do have older patents related to the chemokine modulating protein, M-T7 and have had active research grants funded by the American Heart Association as well as NIH funding.